期刊
DIABETES & VASCULAR DISEASE RESEARCH
卷 13, 期 2, 页码 119-126出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164115616901
关键词
Obesity; body fat distribution; visceral adipose tissue; empagliflozin; sodium glucose co-transporter 2 inhibitor
资金
- Dedman Family Scholarship in Clinical Care from UT Southwestern
- National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health [1K23DK106520-01]
Aims: To determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus. Methods: Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12weeks (cohort 1) or 24weeks (cohort 2) duration. Results: This study comprised 3300 patients (cohort 1, N=823; cohort 2, N=2477). Empagliflozin reduced weight, waist circumference and adiposity indices versus placebo in both cohorts. Adjusted mean (95% confidence interval) change from baseline in empagliflozin versus placebo was -1.7kg (-2.1 to -1.4kg) and -1.9kg (-2.1 to -1.7kg) for body weight (p<0.001); -1.3cm (-1.8 to -0.7cm) and -1.3cm (-1.7 to -1.0cm) for waist circumference (p<0.001); -0.2% (-0.7% to 0.3%; p=0.45) and -0.3% (-0.7% to 0.0%; p=0.08) for estimated total body fat; -0.007 (-0.011 to -0.004) and -0.008 (-0.010 to -0.006) for index of central obesity (p<0.001); and -0.3 (-0.5 to 0.0; p=0.07) and -0.4 (-0.7 to -0.1; p=0.003) for visceral adiposity index in cohorts 1 and 2, respectively. Adipose reductions were seen across most age, sex and waist circumference subgroups. Conclusion: Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据